
    
      This is a Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose Expansion Study to
      Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity
      Study of IO-202 as Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients
      with Monocytic Differentiation and in Relapsed/Refractory Chronic Myelomonocytic Leukemia
      (CMML) Patients.
    
  